BioCentury
ARTICLE | Clinical News

Genentech reports detailed data for Tecentriq in first-line NSCLC

December 15, 2017 3:56 AM UTC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported detailed data from the Phase III IMpower150 trial of Tecentriq atezolizumab (MPDL3280A, RG7446) as first-line treatment of advanced stage IV non-squamous non-small cell lung cancer (NSCLC), including results from a subgroup of patients with a T effector (Teff) gene signature expression biomarker. Teff measures mRNA expression of PD-L1, chemokine CXC motif ligand 9 (CXCL9; MIG) and interferon (IFN) gamma.

Tecentriq is already approved in the U.S. to treat metastatic NSCLC in patients who have progressed during or following platinum-containing chemotherapy. Genentech said it plans to submit the data to regulatory agencies worldwide, including FDA and EMA...